Retargeting oncolytic adenoviruses from their systemic preeminent liver tropism to disseminated tumor foci would highly improve the efficacy of these agents at eradicating tumors. We have replaced the KKTK fiber shaft heparan sulfate glycosaminoglycan-binding domain with an RGDK motif in order to achieve simultaneously liver detargeting and tumor targeting. When inserted into a wild-type backbone, this mutation palliated liver transaminase elevation and hematological alterations in mice. Importantly, when tested in a backbone that redirects E1A transcription towards pRB pathway deregulation, RGD at this novel shaft location also improved significantly systemic antitumor therapy compared with the broadly used RGD location at the HI-loop of the fiber knob domain. Gene Therapy (2012) Keywords: oncolytic adenovirus; fiber shaft; HSG-binding domain; RGD motif; antitumor efficacy INTRODUCTION Oncolytic adenoviruses are promising therapies for cancer treatment owing to their ability to self-amplify at the tumor site. However, systemic delivery of Ad5 results in a rapid clearance from the bloodstream and the sequestration of the virus in the liver, which causes toxicity and a drop in virus bioavailability. 1 As the success of adenoviral therapy depends on the ability of adenoviruses to reach disseminated cancer cells, this liver tropism limits the efficacy of the therapy upon systemic administration. To overcome this limitation, capsid retargeting mutations are under study.
INTRODUCTION
Oncolytic adenoviruses are promising therapies for cancer treatment owing to their ability to self-amplify at the tumor site. However, systemic delivery of Ad5 results in a rapid clearance from the bloodstream and the sequestration of the virus in the liver, which causes toxicity and a drop in virus bioavailability. 1 As the success of adenoviral therapy depends on the ability of adenoviruses to reach disseminated cancer cells, this liver tropism limits the efficacy of the therapy upon systemic administration. To overcome this limitation, capsid retargeting mutations are under study.
To retarget Ad5 to tumor sites, it is necessary to abrogate liver transduction (liver detargeting) and to expose new ligands specific for tumor cells on capsid proteins (tumor targeting). To achieve liver detargeting, several mutations on capsid proteins, such as the double ablation of CAR and integrin binding, have failed to reduce hepatocyte transduction in vivo owing to the role of blood factors in adenovirus liver transduction. 2, 3 Recently, ablation of Factor X binding by the hexon has resulted in successful liver-detargeting, 4, 5 although this might be at the expense of lower tumor targeting. 6 Alternatively, the mutation of the heparan sulfate glycosaminoglycan (HSG) putative-binding site KKTK of the Ad5 fiber shaft domain detargets liver transduction, probably because of affectation of the bending or structure of the fiber. 2, 7, 8 On the other hand, the HI-loop of the fiber knob domain has been used to accommodate a broad range of tumor-selective peptides for tumor targeting [9] [10] [11] Among all peptides incorporated into the HI loop, the CDCRGDCFC motif (known as RGD-4C) has been broadly used and confers on Ad5 a CAR-independent entry mechanism by using aV-b3 and aV-b5 integrins as primary receptors. 12, 13 As integrins are a large family of adhesive receptors involved in the spread and adhesion of tumor cells, the RGD-4C motif leads to the enhancement of tumor cell infectivity and oncolytic effect both in vitro and in vivo. 14 In a previous work, we explored the retargeting properties of the replacement of HSG-binding KKT fiber shaft domain with the RGD peptide. 15 This RGD substitution resulted in increased tumor transduction efficiency in vivo compared with a non-modified vector. Furthermore, such substitution partially reduced liver transduction in mice. In the present study, we evaluated the effects that this modification has on the toxicity and antitumor efficacy of an oncolytic adenovirus. The RGD motif at the shaft KKTK domain increased the bioavailability of an oncolytic adenovirus after systemic administration and, consequently, resulted in improved antitumor efficacy compared with an RGD-4C HI-loop-modified virus.
RESULTS AND DISCUSSION
In the context of an adenoviral vector expressing luciferase, the mutation KKTK-RGDK in the HSG-binding domain of the fiber shaft reduced liver transduction and increased tumor transduction compared with a non-modified vector after intravenous administration. 15 Thus, this modification offers simultaneously the liver-detargeting properties of the KKTK domain deletion and the tumor-targeting properties of the RGD peptide. In order to explore whether this modification has a positive impact on the toxicity and the antitumor activity of oncolytic adenoviruses, the KKTK-RGDK mutation was introduced in an ICOVIR-15 background to create ICOVIR-15K. ICOVIR-15 is an AdD24-RGD-derivative oncolytic adenovirus that incorporates eight extra E2F-responsive sites organized in four palindromes and one extra Sp-1 binding-site upstream of E1A to redirect E1A transcription towards pRB deregulation. 16 ICOVIR-15K was compared for toxicity and antitumor activity with its RGD-4C-modified counterpart, ICOVIR-15, which incorporates the CDCRGDCFC motif inserted into the HI-loop of fiber knob domain (Figure 1a) .
First, to assess whether the reduction in liver transduction observed with KKTK-RGDK-modified adenoviral vectors 15 translates in a milder toxicity profile with oncolytic viruses, Balb/C immunocompetent mice were injected intravenously with ICOVIR-15 or ICOVIR-15K at a dose of 5Â10 10 viral particles (vp) per mouse. Adenoviruses controlling E1A under the wild-type promoter and containing the wild-type fiber or the KKTK-RGDK-modified fiber (wild-type adenovirus (Adwt) and Adwt-RGDK) were also included in this study as controls. Animals were weighed daily and common toxicity events reported in clinical trials after high-dose systemic injection of adenoviruses, such as liver enzymes elevation and hematological alterations, 17 were determined. For oncolytic viruses, these parameters were measured at day 5 after injection as at this time point it is described to occur a toxicity peak of inflammatory response. 18 For non-selective Adwt and Adwt-RGDK viruses, samples were collected at day 3 after injection given the higher lethality of 5Â10 10 vp per mouse with adenoviruses controlling E1A under the wild-type promoter. 19 When aspartate aminotransferase and alanine aminotransferase were analyzed in peripheral blood of mice, up to a 47-and 196-fold elevation was detected, respectively, in Adwt treated mice compared with nontreated animals ( Figure 1b ). However, when mice injected with the same dose of Adwt-RGDK were analyzed, half of these values were detected for both aspartate aminotransferase (Po0.0005) and alanine aminotransferase (Po0.007). Furthermore, the RGDK mutation in the fiber shaft domain was able to significantly palliate hematological alterations, such as thrombocytopenia and lymphopenia, which were otherwise observed after systemic injection of Adwt ( Figure 1c ). After administration of ICOVIR-15 and ICOVIR-15K, no significant differences were observed between both groups in transaminases and hematology (Figures 1b and c) , likely because of the lower toxicity of ICOVIR-15-based viruses which do not express E1a in normal cells.
Besides reducing liver transduction, the RGDK fiber also proved an increase in cancer cell infectivity compared with vectors containing the wild-type fiber. 15 However, this increase was not observed when compared with RGD-4C fiber-containing vectors. Similar in vitro infectivity between RGDK and RGD-4C-containing viruses was corroborated by cytotoxicity assays with tumor cells of different origins, including melanoma, osteosarcoma and pancreatic carcinoma. The RGDK fiber modification was not able to reduce the amount of ICOVIR-15 needed to decrease cell culture viability by 50% (IC 50 ) (Figure 2 ). Despite this similarity in vitro, both viruses displayed different behavior and antitumor activity when tested systemically in mice models.
The attenuation of the liver tropism driven by the KKTK-RGDKmodified fiber may increase the bioavailability of the virus and as a consequence raise the amount of virus that reaches the tumor sites. To detect such increase in bioavailability, viremia kinetics was analyzed by collecting blood samples from mice at different time points after systemic injection of ICOVIR-15 or ICOVIR-15K. As shown in Figure 3a , significant increases in viremia of 11 (Po0.002), 12 (Po0.006) and 2.5 (Po0.002) times were detected in serum after injection of ICOVIR-15K compared with ICOVIR-15 at 5, 15 min and 4 h, respectively.
To test systemic efficacy, mice with NP-18 (pancreatic adenocarcinoma), Skmel-28 (melanoma) and NP-9 (pancreatic adenocarcinoma) tumor models were treated with a single intravenous dose of ICOVIR-15 or ICOVIR-15K at 5Â10 10 vp per mouse or phosphatebuffered saline (PBS). When untreated, animals with NP-18 tumors, an aggressive model of fast-growing pancreatic adenocarcinoma, had to be killed owing to uncontrolled tumor growth at day 28, tumor size of this group was 5.2-fold larger than in mice treated with ICOVIR-15K (Po0.000006) (Figure 3b) . Furthermore, ICOVIR-15K seemed more effective than ICOVIR-15 as tumor size was fourfold larger in the latter group when mice were killed at day 39 (Po0.0009). In mice with Sk-mel28 tumors, the tumor size at day 37 in PBS-treated mice was 3.2-fold higher than in the ICOVIR-15K group (Po0.000009). Moreover, tumors in mice treated with ICOVIR-15 were 2.2-fold larger than those in mice treated with ICOVIR-15K at day 79 (Po0.035). Finally, in mice bearing NP-9 tumors, a tumor model displaying slower growth rate, the tumor size in PBS-treated animals was 5.3-fold larger than in the ICOVIR-15K group at day 60 after administration (Po0.0002). Tumors treated with ICOVIR-15 at the end of the experiment (day 72) were twofold larger than those treated with ICOVIR-15K (Po0.05). Importantly, 3 out of 10 NP-9 tumors of mice treated with a single systemic injection of ICOVIR-15K underwent a complete regression.
The KKTK-RGDK-modified fiber was also able to significantly increase survival of mice carrying different subcutaneous tumor models. As shown in Figure 3c , median survival of PBS-treated mice carrying NP-18 tumors was only 10 days. By contrast, median survival duplicated (23 days, Po0.035) when mice were injected with a single intravenous dose of 5Â10 10 vp of ICOVIR-15, and almost quadrupled (39 days, Po0.004) when the virus injected was ICOVIR-15K. When mice carried Sk-mel28 tumors, median survival of the PBS group was 22 days, whereas it prolonged until 68 days in the ICOVIR-15 group (Po0.0009). When mice carrying the same tumor model were treated with ICOVIR-15K, median survival almost quadrupled to 84 days (Po0.0005). Finally, in the NP-9 model, ICOVIR-15 and ICOVIR-15K treatment prolonged median survival of PBS-injected mice from 51 to 70 and 115 days, respectively (Po0.0001).
Collectively, our data demonstrate that an oncolytic adenovirus presenting a fiber in which the KKTK HSG-binding domain has been replaced by an RGD integrin-binding domain displays an improved systemic efficacy to toxicity ratio compared with its counterpart presenting an HI-loop RGD-modified fiber. This improvement is likely to be mediated by a reduction of the adenovirus liver tropism, which increases the virus bioavailability and allows a higher amount of viruses to reach the tumor sites, but more research is needed to elucidate the exact mechanism of liver detargeting. These results warrant the incorporation of such modification into future oncolytic adenoviruses candidates to be tested in clinical trials.
MATERIALS AND METHODS

Cell culture
HEK293 (human embryonic kidney cells), A549 (lung carcinoma), SkMel-28 (melanoma) and Saos-2 (osteosarcoma) cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). NP-9 and NP-18 (pancreatic adenocarcinomas) cell lines were established in our laboratory. 20 All cell lines were maintained in Dulbecco's modified Eagle's medium containing 5% fetal bovine serum at 37 1C, 5% CO 2 .
Viruses
Human adenovirus serotype 5 (Adwt) was obtained from ATCC and ICOVIR-15 has been previously described. 16 Both viruses were propagated in A549 cells. Adwt-RGDK was created by replacing the wild-type fiber for the RGDK fiber in the adenovirus 5 wild-type genome. To achieve this, an EcoRI digestion fragment of the pBSattKKT plasmid 15 containing the RGK fiber was recombined in Saccharomyces cerevisiae YPH857 with the pVK50-CAU plasmid 21 linearized with SwaI to create pAdwt-RGDK-CAU. Adwt-RGDK was obtained by transfection into HEK293 cells of the large PacI fragment of pAdwt-RGDK-CAU. ICOVIR-15K was constructed taking advantage of an SpeI site present in pICOVIR16-CAU. 16 The pICOVIR-15K-CAU plasmid, containing the complete ICOVIR-15K genome, was created by homologous recombination in yeast between pAdwt-RGDK-CAU, digested with BamHI and PacI, and pICOVIR-16-CAU, digested partially with SpeI. ICOVIR-15K was obtained by transfection in HEK293 cells of the PacI fragment of pICOVIR-15K-CAU. Viruses were plaque-purified, amplified in A549 cells and purified using a CsCl gradient. Viral genomes were verified by restriction analysis and by sequencing E1A promoter, E1A-D24 and fiber using oligonucleotides oligo22 (5¢-AAGTGT GATGTTGCAAGTGT-3¢), Ad670F (5¢-ATCTTCCACCTCCTAGCCAT-3¢) and FiberUp (5¢-CAAACGCTGTTGGATTTATG-3¢).
In vitro cytotoxicity assays
Cytotoxity assays were performed by seeding 15 000 Saos-2 or NP-9 cells, or 10 000 Sk-mel28 per well in 96-well plates in DMEM with 5% FBS. Cells were infected with serial dilutions starting with 800 TU per cell for NP-9 cells, 150 TU per cell for Saos-2 cells or 100 TU per cell for Sk-mel28 cells. At day 5 post-infection, plates were washed with PBS and stained for total protein content (bicinchoninic acid assay ), Pierce Biotechnology, Rockford, IL, USA). Absorbance was quantified and the TU per cell required to produce 50% inhibition (IC 50 value) was estimated from dose-response curves by standard nonlinear regression (GraFit; Erithacus Software, Horley, UK), using an adapted Hill equation.
In vivo toxicity study
Mice for toxicology and efficacy studies were maintained in the facility of the IDIBELL-Institut de Recerca Oncolò gica (Barcelona), AAALAC unit 1155. All animal studies have been approved by the Institut d'Investigacio Biomedica de Bellvitge Ethical Committee for Animal Experimentation. 5Â10 10 purified vp were injected intravenously into the tail vein in 6-week-old immunocompetent Balb/C male mice at 10 ml kg À1 in PBS (n¼5). Daily observations for body weight, morbidity and moribundity were performed. At day 3 or day 5 postinjection, mice were killed and blood samples were collected by intracardiac puncture. Clinical biochemical and hematological determinations were performed by the Clinical Biochemistry and Hematological Services of the Veterinary Faculty at the Autonomous University of Barcelona. The significance of differences in biochemical and hematological rates between treatment groups were assessed by a two-tailed Student's unpaired t-test. 
Determination of adenovirus viremia
Balb/C nu/nu male mice (6-week-old) were injected with a dose of 4Â10 10 purified vp at 10 ml kg À1 in PBS (n¼5). At 5, 15min, 1 and 4h postadministration, blood samples were collected by tail vein sampling. Viral titers were determined in serum by an anti-hexon staining-based method. 19 In vivo antitumoral efficacy Subcutaneous SkMel-28, NP-9 or NP-18 carcinoma tumors were established by injection of 1Â10 7 cells into the flanks of 6-week-old male Balb/C nu/nu mice. When tumors reached 100 mm 3 (experimental day 0), mice were randomized (n¼10-16 per group) and were injected with a single intravenous injection of PBS or 5Â10 10 vp of ICOVIR-15 or ICOVIR-15K at 10 ml kg À1 in PBS via tail vein. Tumor size and mice status were monitored thrice per week. Tumor volume was defined by the equation V (mm 3 )¼p/6ÂW 2 ÂL, where W and L are the width and the length of the tumor, respectively. Data are expressed as relative tumor size with respect the beginning of the therapy, which was set as 100%. The significance of differences in relative tumor size between treatment groups was assessed by a two-tailed Student's unpaired t-test. For Kaplan-Meier survival curves, end point was established at X500 mm 3 . The survival curves obtained were compared for the different treatments. Animals whose tumor size never achieved the threshold were included as right-censored information. A log-rank test was used to determine the statistical significance of the differences in time-to-event.
